Blue Earth Therapeutics

Executive Summary

Blue Earth Therapeutics is a UK-based radiopharmaceutical company founded in 2018 and a subsidiary of Bracco, an Italian diagnostics and imaging leader. The company focuses on developing next-generation targeted radiopharmaceutical therapies (RPTs) that deliver high radiation doses precisely to tumors while minimizing damage to healthy organs, aiming to improve outcomes for cancer patients. Leveraging Bracco's corporate backing and expertise in imaging, Blue Earth is advancing a pipeline of novel radiotherapeutics, likely targeting prostate cancer and other solid tumors. Although specific pipeline details are not publicly disclosed, the company's approach aligns with the rapidly growing field of targeted radionuclide therapy, which has seen significant validation with approved drugs like Pluvicto. With a strong parent company and a clear mission, Blue Earth is positioned to capitalize on the expansion of radiopharmaceuticals, but its early private stage and lack of clinical data introduce uncertainty. The company's success will depend on the advancement of its lead candidates into clinical trials and achieving proof-of-concept.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First-in-Human Clinical Trial for Lead Candidate60% success
• Q2 2026FDA Orphan Drug Designation for a Pipeline Asset70% success
• H1 2026Presentation of Preclinical Data at Major Medical Conference80% success